The Life Sciences team advised Monte Rosa Therapeutics on its Series B financing of $96 million.
Monte Rosa is a biotechnology company focused on developing precision medicines to degrade disease-causing proteins.
The financing will enable Monte Rosa to accelerate the growth of its pipeline, advance development candidates into the clinic and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach Monte Rosa Therapeutics will eradicate undruggable proteins that cause or drive the progression of genomically defined diseases intractable to standard care, including cancer.
The Series B financing was led by Aisling Capital with participation from founding investor Versant Ventures and existing investor New Enterprise Associates. Additional new investors included HBM Healthcare Investments, Cormorant Asset Management, GV, Amzak Health, Casdin Capital, Sixty Degree Capital and Cambridge Asset Management.
The Goodwin team was led by Rob Puopolo, Dan Hughes and included Dan Karelitz.
For more details, read the press release and articles in Endpoints, The Pharma Letter, and Boston Business Journal.